Michael Wang
Researcher Next ID · RN-020402
Researcher · Medicine
University of North Carolina at Chapel Hill
Chapel Hill, New Zealand
- Works count
- 1,143
- Citation count
- 46,252
- H-index
- 96
- i10-index
- 418
Research interests
Publications
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.00562
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00224-5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31366-0
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1914347
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1910607
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.77.8084
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33108-2
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Nature Communications · 2017 · https://doi.org/10.1038/ncomms14920
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Blood · 2016 · https://doi.org/10.1182/blood-2016-04-711903
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Science Signaling · 2016 · https://doi.org/10.1126/scisignal.aac4380
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1411321
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2014.56.2025
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Blood · 2012 · https://doi.org/10.1182/blood-2012-05-425934
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Blood · 2012 · https://doi.org/10.1182/blood-2012-03-414359
An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
British Journal of Haematology · 2012 · https://doi.org/10.1111/j.1365-2141.2012.09232.x
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Blood · 2012 · https://doi.org/10.1182/blood-2011-10-386789
Current projects
No projects listed.